Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

An Integrated Approach for Efficient Multi-Omics Joint Analysis.

Tagliamonte MS, Waugh SG, Prosperi M, Mai V.

ACM BCB. 2019 Sep;2019:619-625. doi: 10.1145/3307339.3343476.

2.

Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders.

Fantuzzi L, Tagliamonte M, Gauzzi MC, Lopalco L.

Cell Mol Life Sci. 2019 Aug 3. doi: 10.1007/s00018-019-03255-6. [Epub ahead of print] Review.

PMID:
31377844
3.

Immunotherapy in hepatocellular carcinoma.

Buonaguro L, Mauriello A, Cavalluzzo B, Petrizzo A, Tagliamonte M.

Ann Hepatol. 2019 Mar - Apr;18(2):291-297. doi: 10.1016/j.aohep.2019.04.003. Epub 2019 Apr 25. Review.

4.

First Genome Sequence of Pasteurella multocida Type B Strain BAUTB2, a Major Pathogen Responsible for Mortality of Bovines in Bangladesh.

Sarker MSA, Rahman MT, Mahmud MM, Tagliamonte MS, Chowdhury SMZH, Islam MR, Rahman MB, El Zowalaty ME, Nazir KHMNH.

Microbiol Resour Announc. 2018 Sep 6;7(9). pii: e00901-18. doi: 10.1128/MRA.00901-18. eCollection 2018 Sep.

5.

Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients.

Petrizzo A, Tagliamonte M, Mauriello A, Costa V, Aprile M, Esposito R, Caporale A, Luciano A, Arra C, Tornesello ML, Buonaguro FM, Buonaguro L.

J Transl Med. 2018 Oct 19;16(1):286. doi: 10.1186/s12967-018-1662-9.

6.

Potentiating cancer vaccine efficacy in liver cancer.

Tagliamonte M, Petrizzo A, Mauriello A, Tornesello ML, Buonaguro FM, Buonaguro L.

Oncoimmunology. 2018 Jul 23;7(10):e1488564. doi: 10.1080/2162402X.2018.1488564. eCollection 2018.

7.

Cellular prognostic markers in hepatitis-related hepatocellular carcinoma.

Petrizzo A, Mauriello A, Tornesello ML, Buonaguro FM, Tagliamonte M, Buonaguro L.

Infect Agent Cancer. 2018 Mar 27;13:10. doi: 10.1186/s13027-018-0183-8. eCollection 2018. Review.

8.

Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting.

Petrizzo A, Mauriello A, Luciano A, Rea D, Barbieri A, Arra C, Maiolino P, Tornesello M, Gigantino V, Botti G, Ciliberto G, Buonaguro FM, Tagliamonte M, Buonaguro L.

Oncotarget. 2017 Dec 8;9(3):3576-3589. doi: 10.18632/oncotarget.23181. eCollection 2018 Jan 9.

9.

Complete Genomic Sequence of Dengue Virus Serotype 4 Isolated from Plasma Collected from a Haitian Child in 2014.

Elbadry MA, White SK, Loeb JC, Tagliamonte MS, Salemi M, Beau De Rochars VM, Telisma T, Rashid M, Morris JG Jr, Lednicky JA.

Genome Announc. 2017 Oct 5;5(40). pii: e01160-17. doi: 10.1128/genomeA.01160-17.

10.

Submicroscopic malaria infections in pregnant women from six departments in Haiti.

Elbadry MA, Tagliamonte MS, Raccurt CP, Lemoine JF, Existe A, Boncy J, Weppelmann TA, Dame JB, Okech BA.

Trop Med Int Health. 2017 Aug;22(8):1030-1036. doi: 10.1111/tmi.12909. Epub 2017 Jul 14.

11.

Complete Genomic Sequence of Dengue virus 1, Isolated from Plasma Collected from a Haitian Child in 2014.

Elbadry M, White S, Loeb J, Tagliamonte M, Salemi M, Beau De Rochars JVM, Okech B, Morris G Jr, Lednicky J.

Genome Announc. 2017 Jun 1;5(22). pii: e00331-17. doi: 10.1128/genomeA.00331-17.

12.

Immunological effects of a novel RNA-based adjuvant in liver cancer patients.

Circelli L, Petrizzo A, Tagliamonte M, Heidenreich R, Tornesello ML, Buonaguro FM, Buonaguro L.

Cancer Immunol Immunother. 2017 Jan;66(1):103-112. doi: 10.1007/s00262-016-1923-5. Epub 2016 Nov 10.

PMID:
27832318
13.

Identification and Validation of HCC-specific Gene Transcriptional Signature for Tumor Antigen Discovery.

Petrizzo A, Caruso FP, Tagliamonte M, Tornesello ML, Ceccarelli M, Costa V, Aprile M, Esposito R, Ciliberto G, Buonaguro FM, Buonaguro L.

Sci Rep. 2016 Jul 8;6:29258. doi: 10.1038/srep29258.

14.

A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice.

Tagliamonte M, Petrizzo A, Napolitano M, Luciano A, Rea D, Barbieri A, Arra C, Maiolino P, Tornesello M, Ciliberto G, Buonaguro FM, Buonaguro L.

J Transl Med. 2016 Feb 24;14:58. doi: 10.1186/s12967-016-0812-1.

15.

Combinatorial immunotherapy strategies for hepatocellular carcinoma.

Tagliamonte M, Petrizzo A, Tornesello ML, Ciliberto G, Buonaguro FM, Buonaguro L.

Curr Opin Immunol. 2016 Apr;39:103-13. doi: 10.1016/j.coi.2016.01.005. Epub 2016 Feb 4. Review.

PMID:
26851637
16.

High prevalence of asymptomatic malaria infections: a cross-sectional study in rural areas in six departments in Haiti.

Elbadry MA, Al-Khedery B, Tagliamonte MS, Yowell CA, Raccurt CP, Existe A, Boncy J, Weppelmann TA, Beau De Rochars VE, Lemoine JF, Okech BA, Dame JB.

Malar J. 2015 Dec 21;14:510. doi: 10.1186/s12936-015-1051-2.

17.

Functional characterization of biodegradable nanoparticles as antigen delivery system.

Petrizzo A, Conte C, Tagliamonte M, Napolitano M, Bifulco K, Carriero V, De Stradis A, Tornesello ML, Buonaguro FM, Quaglia F, Buonaguro L.

J Exp Clin Cancer Res. 2015 Oct 6;34:114. doi: 10.1186/s13046-015-0231-9.

18.

Systems Biology Approach for Cancer Vaccine Development and Evaluation.

Circelli L, Petrizzo A, Tagliamonte M, Tornesello ML, Buonaguro FM, Buonaguro L.

Vaccines (Basel). 2015 Jul 14;3(3):544-55. doi: 10.3390/vaccines3030544. Review.

19.

Malaria elimination in Haiti by the year 2020: an achievable goal?

Boncy PJ, Adrien P, Lemoine JF, Existe A, Henry PJ, Raccurt C, Brasseur P, Fenelon N, Dame JB, Okech BA, Kaljee L, Baxa D, Prieur E, El Badry MA, Tagliamonte MS, Mulligan CJ, Carter TE, Beau de Rochars VM, Lutz C, Parke DM, Zervos MJ.

Malar J. 2015 Jun 5;14:237. doi: 10.1186/s12936-015-0753-9.

20.

Cellular prognostic markers in hepatocellular carcinoma.

Buonaguro L, Tagliamonte M, Petrizzo A, Damiano E, Tornesello ML, Buonaguro FM.

Future Oncol. 2015;11(11):1591-8. doi: 10.2217/fon.15.39. Review.

PMID:
26043213
21.

Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model.

Tagliamonte M, Petrizzo A, Napolitano M, Luciano A, Arra C, Maiolino P, Izzo F, Tornesello ML, Aurisicchio L, Ciliberto G, Buonaguro FM, Buonaguro L.

Cancer Immunol Immunother. 2015 Oct;64(10):1305-14. doi: 10.1007/s00262-015-1698-0. Epub 2015 May 6.

PMID:
25944003
22.

Antigen-specific vaccines for cancer treatment.

Tagliamonte M, Petrizzo A, Tornesello ML, Buonaguro FM, Buonaguro L.

Hum Vaccin Immunother. 2014;10(11):3332-46. doi: 10.4161/21645515.2014.973317. Review.

23.

Influence of ovarian stimulation for IVF/ICSI on the antioxidant defence system and relationship to outcome.

Palini S, Benedetti S, Tagliamonte MC, De Stefani S, Primiterra M, Polli V, Rocchi P, Catalani S, Battistelli S, Canestrari F, Bulletti C.

Reprod Biomed Online. 2014 Jul;29(1):65-71. doi: 10.1016/j.rbmo.2014.03.010. Epub 2014 Mar 26.

PMID:
24813757
24.

Formation of self-assembled triple-layered rotavirus-like particles (tlRLPs) by constitutive co-expression of VP2, VP6, and VP7 in stably transfected high-five insect cell lines.

Shoja Z, Tagliamonte M, Jalilvand S, Mollaei-Kandelous Y, De Stradis A, Tornesello ML, Buonaguro FM, Buonaguro L.

J Med Virol. 2015 Jan;87(1):102-11. doi: 10.1002/jmv.23973. Epub 2014 May 5.

PMID:
24797918
25.

Systems vaccinology for cancer vaccine development.

Petrizzo A, Tagliamonte M, Tornesello M, Buonaguro FM, Buonaguro L.

Expert Rev Vaccines. 2014 Jun;13(6):711-9. doi: 10.1586/14760584.2014.913484. Epub 2014 Apr 28. Review.

PMID:
24766452
26.

Prediction of individual immune responsiveness to a candidate vaccine by a systems vaccinology approach.

Petrizzo A, Tagliamonte M, Tornesello ML, Buonaguro FM, Buonaguro L.

J Transl Med. 2014 Jan 15;12:11. doi: 10.1186/1479-5876-12-11.

27.

MRI anatomical variants of mammillary bodies.

Tagliamonte M, Sestieri C, Romani GL, Gallucci M, Caulo M.

Brain Struct Funct. 2015 Jan;220(1):85-90. doi: 10.1007/s00429-013-0639-y. Epub 2013 Sep 27.

PMID:
24072163
28.

Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate.

Visciano ML, Tagliamonte M, Stewart-Jones G, Heyndrickx L, Vanham G, Jansson M, Fomsgaard A, Grevstad B, Ramaswamy M, Buonaguro FM, Tornesello ML, Biswas P, Scarlatti G, Buonaguro L; NGIN Consortium.

J Transl Med. 2013 Jul 8;11:165. doi: 10.1186/1479-5876-11-165.

29.

Challenges in cancer vaccine development for hepatocellular carcinoma.

Buonaguro L, Petrizzo A, Tagliamonte M, Tornesello ML, Buonaguro FM.

J Hepatol. 2013 Oct;59(4):897-903. doi: 10.1016/j.jhep.2013.05.031. Epub 2013 May 25. Review. Erratum in: J Hepatol. 2014 Jan;60(1):237.

30.

Chemokine receptor interactions with virus-like particles.

Buonaguro L, Tagliamonte M, Visciano ML.

Methods Mol Biol. 2013;1013:57-66. doi: 10.1007/978-1-62703-426-5_5.

PMID:
23625493
31.

Developments in virus-like particle-based vaccines for HIV.

Buonaguro L, Tagliamonte M, Visciano ML, Tornesello ML, Buonaguro FM.

Expert Rev Vaccines. 2013 Feb;12(2):119-27. doi: 10.1586/erv.12.152. Review.

PMID:
23414404
32.

Development of a stable insect cell line constitutively expressing rotavirus VP2.

Shoja Z, Tagliamonte M, Jalilvand S, Mokhtari-Azad T, Hamkar R, Shahmahmoodi S, Rezaei F, Tornesello M, Buonaguro FM, Buonaguro L, Nategh R.

Virus Res. 2013 Mar;172(1-2):66-74. doi: 10.1016/j.virusres.2012.12.015. Epub 2012 Dec 31.

PMID:
23287060
33.

Molecular characterization analysis of the outer protein layer (VP7) from human rotavirus A genotype G1 isolate identified in Iran: implications for vaccine development.

Shoja Z, Tagliamonte M, Jalilvand S, Ziaee AA, Mokhtari-Azad T, Hamkar R, Shahmahmoodi S, Rezaei F, Tornesello M, Buonaguro FM, Nategh R, Buonaguro L.

New Microbiol. 2012 Oct;35(4):415-27. Epub 2012 Oct 1.

34.

HIV p24 as scaffold for presenting conformational HIV Env antigens.

Tagliamonte M, Marasco D, Ruggiero A, De Stradis A, Tornesello ML, Totrov M, Buonaguro FM, Buonaguro L.

PLoS One. 2012;7(8):e43318. doi: 10.1371/journal.pone.0043318. Epub 2012 Aug 17.

35.

Differences in blood and semen oxidative status in fertile and infertile men, and their relationship with sperm quality.

Benedetti S, Tagliamonte MC, Catalani S, Primiterra M, Canestrari F, De Stefani S, Palini S, Bulletti C.

Reprod Biomed Online. 2012 Sep;25(3):300-6. doi: 10.1016/j.rbmo.2012.05.011. Epub 2012 May 30.

PMID:
22818093
36.

Immunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration.

Buonaguro L, Tagliamonte M, Visciano ML, Andersen H, Lewis M, Pal R, Tornesello ML, Schroeder U, Hinkula J, Wahren B, Buonaguro FM.

Clin Vaccine Immunol. 2012 Jun;19(6):970-3. doi: 10.1128/CVI.00068-12. Epub 2012 Mar 29.

37.

Effects of adjuvants on IgG subclasses elicited by virus-like particles.

Visciano ML, Tagliamonte M, Tornesello ML, Buonaguro FM, Buonaguro L.

J Transl Med. 2012 Jan 5;10:4. doi: 10.1186/1479-5876-10-4.

38.

Counteraction of oxidative damage in the rat liver by an ancient grain (Kamut brand khorasan wheat).

Benedetti S, Primiterra M, Tagliamonte MC, Carnevali A, Gianotti A, Bordoni A, Canestrari F.

Nutrition. 2012 Apr;28(4):436-41. doi: 10.1016/j.nut.2011.08.006. Epub 2011 Nov 29.

PMID:
22129853
39.

The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: a multicentric study.

Fimiani B, Guardia DD, Puoti C, D'Adamo G, Cioffi O, Pagano A, Tagliamonte MR, Izzi A.

Eur J Intern Med. 2011 Dec;22(6):587-90. doi: 10.1016/j.ejim.2011.06.013. Epub 2011 Aug 2.

PMID:
22075285
40.

Developments in virus-like particle-based vaccines for infectious diseases and cancer.

Buonaguro L, Tagliamonte M, Tornesello ML, Buonaguro FM.

Expert Rev Vaccines. 2011 Nov;10(11):1569-83. doi: 10.1586/erv.11.135. Review.

PMID:
22043956
41.

Can HIV p24 be a suitable scaffold for presenting Env antigens?

Buonaguro L, Tagliamonte M, Tornesello ML, Buonaguro FM.

Clin Vaccine Immunol. 2011 Nov;18(11):2003-4. doi: 10.1128/CVI.05326-11. Epub 2011 Sep 7. No abstract available.

42.

HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line.

Tagliamonte M, Visciano ML, Tornesello ML, De Stradis A, Buonaguro FM, Buonaguro L.

Vaccine. 2011 Jul 12;29(31):4913-22. doi: 10.1016/j.vaccine.2011.05.004. Epub 2011 May 17.

PMID:
21596085
43.

Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins.

Visciano ML, Diomede L, Tagliamonte M, Tornesello ML, Asti V, Bomsel M, Buonaguro FM, Lopalco L, Buonaguro L.

Vaccine. 2011 Jul 12;29(31):4903-12. doi: 10.1016/j.vaccine.2011.05.005. Epub 2011 May 17.

PMID:
21596074
44.

Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies.

Tagliamonte M, Tornesello ML, Buonaguro FM, Buonaguro L.

J Transl Med. 2011 Jan 27;9 Suppl 1:S1. doi: 10.1186/1479-5876-9-S1-S1. Review.

45.

Quantitative HIV-1 proviral DNA detection: a multicentre analysis.

De Rossi A, Zanchetta M, Vitone F, Antonelli G, Bagnarelli P, Buonaguro L, Capobianchi MR, Clementi M, Abbate I, Canducci F, Monachetti A, Riva E, Rozera G, Scagnolari C, Tagliamonte M, Re MC; SIVIM (Italian Society of Medical Virology) Group.

New Microbiol. 2010 Oct;33(4):293-302.

46.

Constitutive expression of HIV-VLPs in stably transfected insect cell line for efficient delivery system.

Tagliamonte M, Visciano ML, Tornesello ML, De Stradis A, Buonaguro FM, Buonaguro L.

Vaccine. 2010 Sep 7;28(39):6417-24. doi: 10.1016/j.vaccine.2010.07.054. Epub 2010 Aug 2.

PMID:
20678589
47.

Human papillomavirus infection in urine samples from male renal transplant patients.

Tornesello ML, Loquercio G, Tagliamonte M, Rossano F, Buonaguro L, Buonaguro FM.

J Med Virol. 2010 Jul;82(7):1179-85. doi: 10.1002/jmv.21784.

PMID:
20513081
48.

Molecular and phylogenetic analysis of HIV-1 variants circulating in Italy.

Buonaguro L, Petrizzo A, Tagliamonte M, Vitone F, Re MC, Pilotti E, Casoli C, Sbreglia C, Perrella O, Tornesello ML, Buonaguro FM.

Infect Agent Cancer. 2008 Oct 10;3:13. doi: 10.1186/1750-9378-3-13.

49.

HIV type 1 subtype A epidemic in injecting drug user (IDU) communities in Iran.

Tagliamonte M, Naderi HR, Tornesello ML, Farid R, Buonaguro FM, Buonaguro L.

AIDS Res Hum Retroviruses. 2007 Dec;23(12):1569-74. Erratum in: AIDS Res Hum Retroviruses. 2008 Feb;24(2):345.

PMID:
18160015
50.

Genetic and phylogenetic evolution of HIV-1 in a low subtype heterogeneity epidemic: the Italian example.

Buonaguro L, Tagliamonte M, Tornesello ML, Buonaguro FM.

Retrovirology. 2007 May 21;4:34. Review.

Supplemental Content

Loading ...
Support Center